Michael Kenneth Keng MD

PubMed

• 1 citations
  Evaluation of Gemtuzumab Ozogamicin and Anthracycline Dosing for Favorable Risk Acute Myeloid Leukemia.
  Joseph F Mort, David Brighton, Samantha DiBenedetto, Leah Wells, Stephen M Clark
  European Journal of Haematology. 2025-03-01
• Development and Implementation of Oral Anticancer Agent Tools for a Thematic Quality Improvement Program: A Collaboration Between Hematology Oncology Pharmacist Associ...
  Victoria Nachar, Marjorie Adams Curry, Diana Kostoff, Angela Wood, Karen B Farris
  JCO Oncology Practice. 2025-01-23
• 1 citations
  MRD in Philadelphia Chromosome-Positive ALL: Methodologies and Clinical Implications.
  Valerie Tran, Kiarash Salafian, Kenan Michaels, Caroline Jones, Daniel Reed
  Current Hematologic Malignancy Reports. 2024-08-01

Abstracts/Posters

• Distance Does Not Matter: Excellent Survival Outcomes for Leukemia Patients in Rural Appalachia
  Michael K Keng, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Clinical and Immunologic Activity of Ipilimumab Following Decitabine Priming in Post-Allogeneic Transplant and Transplant-Na¥ve Patients with Relapsed or Refractory My...
  Michael Keng, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019

Lectures

• Oral Regimen for Urine Alkalization in Patients Receiving High Dose Methotrexate during a National Shortage of Intravenous Sodium Bicarbonate 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018